Uterine neoplasms, version 1.2014. Journal of the National Comprehensive Cancer Network Koh, W., Greer, B. E., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Chan, J., Cho, K. R., Cohn, D., Crispens, M. A., DuPont, N., Eifel, P. J., Fader, A. N., Fisher, C. M., Gaffney, D. K., George, S., Han, E., Huh, W. K., Lurain, J. R., Martin, L., Mutch, D., Remmenga, S. W., Reynolds, R. K., Small, W., Teng, N., Tillmanns, T., Valea, F. A., McMillian, N., Hughes, M. 2014; 12 (2): 248-280


Adenocarcinoma of the endometrium (also known as endometrial cancer or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. An estimated 49,560 new uterine cancer cases will occur in 2013, with 8190 deaths resulting from the disease. Uterine sarcomas (stromal/mesenchymal tumors) are uncommon malignancies, accounting for approximately 3% of all uterine cancers. The NCCN Guidelines for Uterine Neoplasms describe malignant epithelial carcinomas and uterine sarcomas; each of these major categories contains specific histologic groups that require different management. This excerpt of these guidelines focuses on early-stage disease.

View details for PubMedID 24586086